CD6 and psoriasis: The anti-CD6 antibody Itolizumab is clinically used to treat patients with psoriasis in Asia and has been proposed to alter T cell polarization programs by modulating intracellular signaling pathways controlled by CD6, as opposed to depleting CD6+ T cells36–38.